Drug intelligence / Profile preview

MSC2

Development stage: Preclinical
Lead developer: SanBio
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

MSC2 is a mesenchymal stem cell therapy developed by SanBio for the treatment of nervous system and eye diseases. The drug is currently in preclinical development, with active indications including inflammation and optic neuritis. Its mechanism of action is presumed to involve the immunomodulatory and regenerative properties typical of mesenchymal stem cells, which can modulate immune responses, reduce inflammation, and promote tissue repair. The primary therapeutic areas under investigation are nervous system diseases and eye diseases[1].

Other names: MSC2(SanBio)

Beyond the preview

Go deeper on MSC2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSC2.

Explore the full profile